Pre-Market Earnings Report for October 24, 2025 : PG, SNY, HCA, GD, ITW, BAH, GNTX, FLG, FHB, KOF, STEL, VRTS

A diverse group of companies, including Procter & Gamble, Sanofi, HCA Healthcare, and General Dynamics, are scheduled to report Q3 2025 earnings on October 24, 2025, with analyst consensus forecasts showing a mixed outlook. HCA Healthcare and General Dynamics are projected for strong double-digit EPS growth (11.88% and 11.34% respectively), often with P/E ratios suggesting higher growth potential than their industries. In contrast, Booz Allen Hamilton and Stellar Bancorp face consensus forecasts for significant year-over-year EPS declines, while several firms like Illinois Tool Works and First Hawaiian have consistently beaten analyst expectations in prior quarters.

Analysis

A diverse group of companies is set to report Q3 2025 earnings on October 24, 2025, presenting a mixed outlook based on consensus EPS forecasts and historical performance. HCA Healthcare (HCA) projects an 11.88% YoY EPS increase and has consistently beaten analyst expectations, including a 10.5% beat in Q2. General Dynamics (GD) also forecasts an 11.34% EPS increase, though it previously missed Q3 2024 consensus by 5.37%.

Illinois Tool Works (ITW) and First Hawaiian (FHB) demonstrate operational consistency, having beaten expectations every quarter in the past year, alongside positive EPS growth forecasts of 1.51% and 8.33% respectively. Sanofi (SNY) shows a modest 1.91% EPS increase and trades at a 2025 P/E of 11.13, notably below its industry average of 14.80.

Conversely, Booz Allen Hamilton (BAH) and Stellar Bancorp (STEL) face significant projected EPS decreases of 17.68% and 20.63% YoY, respectively. Gentex (GNTX) is also forecast for an 11.32% EPS decline and missed Q4 2024 consensus by 20.41%, while Coca Cola Femsa (KOF) anticipates an 8.78% EPS decrease and missed its Q2 2025 consensus by 14.47%. Flagstar Bank (FLG) shows a negative EPS forecast and P/E ratio.

Valuation metrics vary, with HCA, GD, ITW, FHB, and STEL exhibiting P/E ratios implying higher earnings growth than their respective industries. In contrast, Procter & Gamble (PG), SNY, BAH, and Virtus Investment Partners (VRTS) trade at P/E ratios below their industry averages, suggesting potential undervaluation or differing market expectations.

Key Decisions for Investors

• Investors should closely monitor HCA Healthcare (HCA) and First Hawaiian (FHB) for continued strong performance given their consistent history of beating expectations and positive EPS growth forecasts.
• Exercise caution with Booz Allen Hamilton (BAH), Gentex (GNTX), and Coca Cola Femsa (KOF) due to significant projected EPS declines and recent misses, despite some historical beats for BAH.
• Evaluate Sanofi (SNY), Procter & Gamble (PG), and Virtus Investment Partners (VRTS) for potential value, considering their P/E ratios are below industry averages, but factor in PG's and VRTS's projected EPS decreases.
• Scrutinize General Dynamics (GD) and Illinois Tool Works (ITW) for their ability to meet high growth expectations, especially GD given its recent miss, despite P/E ratios implying superior industry growth.